Redeye’s initial take on the OPEX in Q4 being temporarily high is bolstered after a deeper dive into...
Förvaltningsresultat ökade med 25% på årsbasis och substansvärdet uppgår till 207 kronor.
Suominen's Q4 comparable EBITDA remained virtually intact q/q, but fell short of Vara Research conse...
Small miss on underlying PTP in Q4 Higher non-recurring items than expected Fair value range down to...
Underlying earnings better than expected 4.2% organic sales growth in Q4 Near-term uncertainty persi...
Redeye comments on Better Collective’s updated financial targets where it narrows its EBITDA-margin ...
EBITA SEK 177m (-11% vs. ABGSCe, -9% vs. cons) We expect cons.
Redeye ger en kort kommentar om försäljningssiffrorna för Leqembi under Q4 2023, som var lägre än vä...
Q4 EBITDA of 21.5m vs ABGSCe 20.1m Initiates strategic review of portfolio Downwards revision to con...
Suominen’s Q4 was expected to show some further recovery in earnings, but its pace still turned out ...
More baseline falls vs. expected implies higher likelihood of effect New guidance: completion of stu...
Redeye sees a Q4 with sales coming in according to our estimates, but we note that costs came in hig...
Board recommends shareholders to REJECT Kingspan bid Increases the chance of a raised bid, in our vi...
Redeye retains its positive view on Lagercrantz following a Q3 report in-line with our estimates.
Redeye comments on Scandion Oncology presenting more details on CORIST part 3 results at its recent ...
Redeye was surprised, not to say shocked, to see the Acconeer press release of a wipeout rights issu...
Q4e revenue ~NOK 306m Sainsbury's contract a positive development, but more orders needed Estimates ...
Redeye comments on Artificial Solution's announcement of the outcome of the rights issue.
Redeye shares its preview of BONESUPPORT’s Q4 2023e results, due February 15.
Enersense will build three 110kV power grid substations in Finland.
